- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.01. | BiomX Inc: BiomX Issues Statement Regarding Recent Common Stock Trading Activity | 121 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 27.01. | Morning Market Movers: Nuwellis, BiomX, Brand Engagement Network, Blaize Holdings See Big Swings | 333 | AFX News | WOONSOCKET (dpa-AFX) - At 7:02 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 14.01. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | BiomX Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 29.12.25 | BiomX Inc: BiomX Announces $3.0 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 17.12.25 | BiomX collapses into court proceedings after clinical trial fails | 6 | CTech | ||
| 08.12.25 | BiomX Inc: BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review | 184 | GlobeNewswire (Europe) | Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in... ► Artikel lesen | |
| 08.12.25 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.11.25 | H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries | 10 | Investing.com | ||
| 28.11.25 | BiomX: H.C. Wainwright bestätigt Kaufempfehlung trotz FDA-Rückfragen zum Inhalator | 5 | Investing.com Deutsch | ||
| 26.11.25 | BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review | 8 | Benzinga.com | ||
| 26.11.25 | BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 | 1 | RTTNews | ||
| 25.11.25 | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis | 242 | GlobeNewswire (Europe) | The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used... ► Artikel lesen | |
| 25.11.25 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | BiomX to implement 1-for-19 reverse stock split on November 25 | 1 | Investing.com | ||
| 14.11.25 | BiomX announces 1-for-19 reverse stock split | 4 | Seeking Alpha | ||
| 14.11.25 | BiomX Inc. Announces 1-for-19 Reverse Stock Split | 201 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 12.11.25 | BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections | 2 | Seeking Alpha | ||
| 12.11.25 | BiomX GAAP EPS of $0.29 | 2 | Seeking Alpha |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| AMGEN | 325,15 | +0,06 % | Sanofi und Amgen: Droht diesem Ansatz das Aus? AKTIONÄR-Tipp profitiert! | Viele große Pharma- und Biotech-Firmen sind auf der Suche nach neuen Behandlungsansätzen für die Atopische Dermatitis (Neurodermitis). So auch die großen Branchenvertreter Amgen und Sanofi, die mit... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,365 | -0,27 % | Defence Therapeutics Inc.: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform | Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,860 | +1,42 % | Cardiol Therapeutics legt Emissionsgarantievertrag und Optionsscheinvereinbarung vor | ||
| REDHILL BIOPHARMA | 1,070 | +7,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| KYNTRA BIO | 6,850 | -2,84 % | FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum | Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen | |
| LEXAGENE | - | - | SOLARIA ENERGIA Y MEDIOAMBIENTE, S.A.: Solaria reports it has signed an agreement with Stoneshield Capital to create a new joint venture, Gravyx, specialising in standalone batteries. | ||
| ARMATA PHARMACEUTICALS | 6,700 | +0,75 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia | FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study
First bacteriophage company to advance a clinical candidate... ► Artikel lesen | |
| VAXCYTE | 47,400 | -0,42 % | Vaxcyte, Inc.: Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 5,450 | -7,63 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts | - Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity-... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics | NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,605 | +4,42 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BIOMX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,660 (-14,22 %) liegt der Kurs bei 3,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.